Market
Market leader in lung cancer treatments by end of 2025?
2
Resolution / Starting Odds
Johnson & Johnson • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Market analysis reports from industry analysts
Story
Johnson & Johnson's RYBREVANT and LAZCLUZE Outperform Tagrisso, Promising Over One Year Survival Improvement Over Osimertinib
Jan 7, 2025, 01:11 PM
Johnson & Johnson announced that its lung cancer treatment, a combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), has shown a statistically significant and clinically meaningful improvement in overall survival compared to osimertinib. In a head-to-head study, this combination therapy outperformed AstraZeneca’s Tagrisso, which could potentially alter the standard of care for lung cancer, one of the most lethal tumor types. The company indicated that the median overall survival improvement is expected to exceed one year.
View original story
Similar markets
AstraZeneca/Daiichi Sankyo • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
Other • 25%
AstraZeneca • 25%
Pfizer • 25%
Roche • 25%
Leading • 25%
Lower • 25%
Third • 25%
Second • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 10% • 25%
Other • 25%
Viking Therapeutics • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Focus on internal development • 25%
Another acquisition in oncology • 25%
Partnership with another biotech • 25%
Other strategic move • 25%
Other • 25%
Competitor drug leads market • 25%
LEQEMBI leads market • 25%
No clear market leader • 25%
Canada • 25%
Japan • 25%
Other • 25%
European Union • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Gastrointestinal Cancer • 25%
Yes • 50%
No • 50%
Merck & Co. • 25%
Pfizer • 25%
Other • 25%
Bristol-Myers Squibb • 25%
